Hot Topics in Hepatitis B: New Clinical Tools for Hepatitis B Management

Description

Join the experts in this session to learn about highly relevant, clinical hot topic issues for hepatitis B management in 2025. Topics include: quantitative HBsAg testing in clinical practice; HCC risk calculators; noninvasive testing for hepatic fibrosis; and metabolic dysfunction-associated steatotic liver disease in patients with HBV infection. 

Journey Maps

Presentations

8:00 AM - 8:15 AM
Nov 08 2025
San Diego, CA

Quantitative Hepatitis B Surface Antigen Testing in Clinical Practice: Different Sources of Production, Prognostic Value, and Using Results to Guide Initiation of Treatment

Scott K. Fung, MD, FRCPC, FAASLD, Presenter
Hepatitis
8:15 AM - 8:30 AM
Nov 08 2025
San Diego, CA

Noninvasive Tests to Assess Hepatic Fibrosis in Chronic Hepatitis B: Elastography, FIB-4, APRI, and ELF Score

Richard Sterling, MD, MSc, FAASLD, Presenter
Hepatitis
8:30 AM - 8:45 AM
Nov 08 2025
San Diego, CA

Hepatocellular Carcinoma Calculators in Clinical Practice: REACH-B, mPAGE, GALAD, and ALBI Scores, and Special Populations

Terry Cheuk-Fung Yip, PhD, Presenter
Hepatitis
8:45 AM - 9:00 AM
Nov 08 2025
San Diego, CA

Metabolic Dysfunction-Associated Steatotic Liver Disease and Hepatitis B Infection (Met-HBV): Epidemiology, Serologic Profile, and Histology Studies

Helena Cortez-Pinto, MD, PhD, FAASLD, Presenter
Hepatitis
9:00 AM - 9:15 AM
Nov 08 2025
San Diego, CA

Metabolic Dysfunction-Associated Steatotic Liver Disease and Hepatitis B: Clinical Management and Outcomes—Cirrhosis, Hepatocellular Carcinoma Risk, Cardiovascular Risk, and Seroclearance Rates

Mandana Khalili, MD, Presenter
Hepatitis

Objectives

  • Explain the clinical utility of quantitative HBsAg testing in the management of chronic hepatitis B infection.
  • Describe how to estimate HCC risk in patients with chronic hepatitis B infection based on risk calculators.
  • Review the assessment of hepatic fibrosis using noninvasive testing in patients with chronic hepatitis B infection.
  • Summarize the impact of MASLD/ MASH in patients with chronic hepatitis B infection in terms of clinical outcomes.
Chair

Marc G. Ghany, MD, MHSc, FAASLD

NIH/NIDDK